Aducanumab is a therapeutic antibody which is directed against the lesion which characterized Alzheimer disease. During the main trial which name is EMERGE aducanumab showed a clear efficacy on the lesions as imaged by PET scans.
Unfortunately, cognitive function didn’t show a significant improvement in treated patients.
Then came a re-analysis of data.
Patients who received a higher dose of aducunumab during a longer duration of treatment did show a significant improvement of their cognitive function.
This is a very important result in the field of Alzheimer disease
https://www.biospace.com/article/releases/biogen-plans-regulatory-filing-for-aducanumab-in-alzheimer-s-disease-based-on-new-analysis-of-larger-dataset-from-phase-3-studies
https://www.neurologylive.com/clinical-focus/aducanumab-heads-to-the-fda-after-biogen-analysis-proves-positive-in-early-alzheimer-disease
FDA’s Biosimilars Action Plan
Il y a 17 heures
Aucun commentaire:
Enregistrer un commentaire